|

HLX04 Clinical Trials

2 actively recruiting trials

Also known as: Bevacizumab

Pipeline

Phase 2: 1Phase 2/3: 1

Top Sponsors

  • Shanghai Henlius Biotech2

Indications

  • Cancer2
  • Liver Disease1
  • Carcinoma, Hepatocellular1
  • Liver Cancer1
  • Metastatic Colorectal Cancer1

Other2 trials

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
Phase 2/3
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.